15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 21 firms covering Ionis Pharmaceuticals Inc, 17 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $60.00 to $129.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $93.68 sits 65% above the current $56.66. The rating mix has stayed broadly stable, with Buy-side ratings easing from 18 to 17 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.89 next quarter toward $-1.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 ratings
Strong Buy
Strong Buy15%
Buy1676%
Hold419%
Sell00%
Strong Sell00%
Based on 21 analysts giving stock ratings to Ionis Pharmaceuticals Inc.
As of Sep, 17 of 21 firms rate IONS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IONS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.89
Range $-1.20 – $-0.61 · 8 analysts · -23% YoY
Next period, 8 analysts expect Ionis Pharmaceuticals Inc to earn $-0.89 a share (range $-1.20 – $-0.61), versus $-1.15 a year earlier. Full-year consensus is $-2.72, growing to $-1.09 the year after.
REVENUE · NEXT QUARTER
$231.3M
Range $205.6M – $288.0M · 8 analysts · +14% YoY
Revenue is expected to reach $231.3M (range $205.6M – $288.0M), +13.9% year-over-year. Full-year consensus is $913.4M, rising to $1.4B next year.
Top analysts covering Ionis Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IONS.
#1
Luca Issi
RBC Capital · Rank #1
Buy
$85.00+50.0% to target
Overall win rate
55%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Buy
$76.00+34.1% to target
Overall win rate
53%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$89.00+57.1% to target
Overall win rate
44%
+ Follow
#4
Jason Gerberry
B of A Securities · Rank #125
Buy
$93.00+64.1% to target
Overall win rate
46%
+ Follow
#5
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$115.00+103.0% to target
Overall win rate
34%
+ Follow
IONS stock forecast FAQ
What is IONS's average 12-month price target?+
The 19 analysts with a live target average $93.68 for Ionis Pharmaceuticals Inc over the next 12 months, ranging from a $129.00 high to a $60.00 low.
Is IONS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 21 analyst ratings, 17 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IONS?+
The Street-high target is $129.00 (Leerink Partners), and the Street-low is $60.00 (BMO Capital). The average of all 19 active targets is $93.68.
How many Wall Street analysts cover IONS?+
21 analysts have an active rating on Ionis Pharmaceuticals Inc, and 19 firms carry a live 12-month price target.
Who is the most accurate analyst covering IONS?+
Among analysts who currently cover IONS, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $85.00 target.
What is Ionis Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.89 per share (range $-1.20 – $-0.61) across 8 analysts. Full-year EPS is projected at $-2.72, rising to $-1.09 the following year.
How much revenue is Ionis Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $231.3M (range $205.6M – $288.0M). Full-year revenue is projected at $913.4M, growing to $1.4B next year.
Have analysts been upgrading or downgrading IONS lately?+
As of Sep, 17 of 21 firms rate IONS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IONS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
